Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal
23/04/2025 06:19
April 23 (Reuters) - Switzerland's Xlife Sciences AG XLS.S said on Wednesday its portfolio company, VERAXA Biotech AG, will merge with Voyager Acquisition VACH.O in a deal that will value the combined company at $1.64 billion. (Reporting by Bipasha Dey in Bengaluru; Editing by Janane Venkatraman) ((Bipasha.Dey@thomsonreuters.com;))
Recent news on Veraxa Biotech AG
See all newsBrief: Veraxa Biotech Holding AG - Files To Register Resale Of Up To 25 Million Ordinary Shares - SEC Filing
Brief: Veraxa Biotech Shareholders Approve All Proposals At Extraordinary General Meeting, Strengthening Strategic Flexibility For Future Growth
Brief: Veraxa Biotech Initiates Cell Line Development With ATUM
NASDAQ RESUMED AT 01:08 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:24 AM